← Back to Clinical Trials
Recruiting NCT07267819

NCT07267819 Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07267819
Status Recruiting
Phase
Sponsor Uniformed Services University of the Health Sciences
Condition Migraine
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2025-08-05
Primary Completion 2028-06-06

Trial Parameters

Condition Migraine
Sponsor Uniformed Services University of the Health Sciences
Study Type OBSERVATIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-08-05
Completion 2028-06-06
Interventions
Xeomin (incobotulinumtoxinA)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This cohort study aims to compare the efficacy of Xeomin injections for migraine management in patients with a history of Traumatic Brain Injury (TBI) versus those with a history of Anomalous Health Incidents (AHI). The study will be conducted at the National Intrepid Center of Excellence (NICOE) in Bethesda, MD. The primary objective is to determine if Xeomin injections result in different outcomes for migraine management between TBI and AHI patients. This is a combined retrospective and prospective cohort study design. Patients scheduled for Xeomin treatments will be categorized into TBI and AHI groups. For the prospective cohort, participants will complete a baseline questionnaire, receive their scheduled Xeomin treatment, and participate in follow-up interviews at 4-6 weeks and 10-12 weeks post-treatment. For the retrospective cohort, similar information will be acquired from existing records. Statistical analysis will compare migraine characteristics and treatment responses between the two groups. All data will be de-identified to protect patient privacy.

Eligibility Criteria

Inclusion Criteria: * At least 18 years of age * Able to provide written consent in English * An employee of the US Government, or an adult family member of a US Government employee * Have received Xeomin treatment to prevent migraine related to TBI or AHI at a Military Treatment Facility or other US Medical Facility * Able to participate in at least 80% of the assessments * A US Citizen and not a dual national of the country where you are currently located Exclusion Criteria: * Prisoner * Decisionally impaired and unable to provide informed consent * Non-US citizen

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology